Video

Q&A With Ayman Tourbah From University Hospital of Reims: Treatment For Progressive Multiple Sclerosis Still Lags Behind Relapsing Form

Author(s):

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form. That is starting to change as more therapies and medications work their way through the regulatory approval process.

Professor Ayman Tourbah from the University Hospital of Reims in France discussed what can be done to help level the playing field in the treatment of this form of the disease during the ECTRIMS conference in Barcelona.

While there are considerably more treatment options available for relapsing multiple sclerosis there is considerable research being conducted to help patients with primary progressive multiple sclerosis.

Related Videos
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
© 2024 MJH Life Sciences

All rights reserved.